SECUKINUMAB FOR TREATMENT OF PATIENTS WITH REFRACTORY PSORIASIS


Cite item

Full Text

Abstract

Refractory psoriasis with a pronounced negative impact on the quality of life of patients is a high percentage. This disease is a difficult therapeutic task, both from a clinical and scientific point of view that indicates search relevance for new methods of treatment. Convincing data confirming the central role of interleukin-17 in the pathogenesis of psoriasis and the importance of biological therapy aimed at interleukin-17 in the treatment of moderate and severe psoriasis, suggest secukinumab as one of the most promising of the currently existing drugs.

About the authors

O. Yu Olisova

Department of skin and venereal diseases of I.M. Sechenov First Moscow State Medical University (Sechenov University)

119435, Moscow, Russian Federation

Victoria O. Nikuradze

Department of skin and venereal diseases of I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: victorianikuradze@gmail.com
postgraduate of the Department of skin and venereal diseases of I.M. Sechenov First Moscow State Medical University (Sechenov University), 119435, Moscow, Russian Federation 119435, Moscow, Russian Federation

References

  1. Qian H., Wang M., Wang Y., Ying W., Zhang J., Huan Y., et al. Role of Galphaq in pathogenesis of psoriasis, a new mechanism about the immune regulation in psoriasis. Int. Immunopharmacol. 2019; (68): 185-92. doi: 10.1016/j.intimp.2018.12.054.
  2. Dopytalska K., Sobolewski P., Błaszczak A., Szymańska E. Psoriasis in special localizations. Reumatologia. 2018; 56(6): 392-8.
  3. Takeshita J., Grewal S., Langan S.M., Mehta N.N., Ogdie A., Van Voorhees A.S., Gelfand J.M. Psoriasis and comorbid diseases: Epidemiology. J. Am. Acad. Dermatol. 2017; 76(3): 377-90.
  4. Знаменская Л.Ф., Мелехина Л.Е., Богданова Е.В., Минеева А.А. Заболеваемость и распространенность псориаза в Российской Федерации. Вестник дерматологии и венерологии. 2012; (5): 20-9.
  5. Michalek I.M., Loring B., John S.M. A systematic review of worldwide epidemiology of psoriasis. J. Eur. Acad. Dermatol. Venereol. 2017; 31(2): 205-12.
  6. Pacheco R.L. Hosni N.D., Latorraca C.O.C., Martimbianco A.L.C., Pachito D.V., Yarak S., Riera R. What do Cochrane systematic reviews say about interventions for treating psoriasis? Sao Paulo Med. J. 2018; 136(4): 354-60.
  7. Толмачева Н.В., Анисимова А.С. Современный взгляд на этиологию и патогенез псориаза. Фундаментальные исследования. 2015; 10(1): 2118-21.
  8. Fleming P., Kraft J., Gulliver W.P., Lynde C. The relationship of obesity with the severity of psoriasis: a systematic review. J. Cutan. Med. Surg. 2015; 19(5): 450-6.
  9. O’Rielly D.D., Rahman P. Genetic, epigenetic and pharmacogenetic aspects of psoriasis and psoriatic arthritis. Rheum. Dis. Clin. North Am. 2015; 41(4): 623-42.
  10. Gordon K.B. Translating the science of psoriasis. Semin. Cutan. Med. Surg. 2016; 35(4, Suppl 4): S64.
  11. Wang Y., Wang L., Yang H., Yuan W., Ren J., Bai Y. Activated circulating T follicular helper cells are associated with disease severity in patients with psoriasis. J. Immunol. Res. 2016; 2016: 7346030.
  12. Lynde C.W., Poulin Y., Vender R., Bourcier M., Khalil S. Interleukin 17A: toward a new understanding of psoriasis pathogenesis. J. Am. Acad. Dermatol. 2014; 71(1): 141-50.
  13. Marzano A.V., Fanoni D., Antiga E., Quaglino P., Caproni M., Crosti C., et al. Expression of cytokines, chemokines and other effector molecules in two prototypic autoinflammatory skin diseases, pyoderma gangrenosum and Sweet’s syndrome. Clin. Exp. Immunol. 2014; 178(1): 48-56.
  14. Reich A., Kaszuba A., Krasowska D., Adamski Z., Chodorowska G. Psoriasis. Diagnostic and therapeutic recommendations of the Polish Dermatological Society. Part I: Mild psoriasis. Przeglad Dermatologiczny. 2018; 105(2): 225-43. doi: 10.5114/dr.2018.75580.
  15. Ronholt K., Iversen L. Old and new biological therapies for psoriasis. Int. J. Mol. Sci. 2017; 18(11): E2297.
  16. Singh K., Argaez C. Cyclosporine for moderate to severe plaque psoriasis in adults: a review of clinical effectiveness and safety. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health, 2018. CADTH Rapid Response Reports.
  17. Dauden E., Puig L., Ferrandiz C., Sanchez-Carazo J.L., Hernanz-Hermosa J.M.; Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology. Consensus document on the evaluation and treatment of moderate-to-severe psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology. J. Eur. Acad. Dermatol. Venereol. 2016; 30(Suppl. 2): 1-18. doi: 10.1111/jdv.13542.
  18. Кунгуров Н.В., Зильберберг Н.В., Кохан М.М., Кениксфест Ю.В., Гришаева Е.В. Опыт применения препарата секукинумаб в терапии тяжелого резистентного псориаза. Лечащий врач. 2017; (11): 17-23.
  19. Криницына Ю.М., Онипченко В.В. Опыт применения генно-инженерного биологического препарата секукинумаб у пациента с псориазом ногтей. Русский медицинский журнал. 2018; (5): 60-4.
  20. Frieder J., Kivelevitch D., Menter A. Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis. Ther. Adv. Chronic Dis. 2018; 9(1): 5-21.
  21. Круглова Л.С., Моисеев С.В. Блокада интерлейкина-17 - новые горизонты эффективности и безопасности в лечении псориаза. Клиническая фармакология и терапия. 2017; 2: 5-12.
  22. Papp K.A., Tyring S., Lahfa M., Prinz J., Griffiths C.E., Nakanishi A.M., et al.; Etanercept Psoriasis Study Group. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br. J. Dermatol. 2005; 152(6): 1304-12.
  23. Mrowietz U., de Jong E.M., Kragballe K., Langley R., Nast A., Puig L., et al. A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis. J. Eur. Acad. Dermatol. Venereol. 2014; 28(4): 438-53.
  24. Bissonnette R., Luger T., Thaci D., Toth D., Lacombe A., Xia S., et al. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). J. Eur. Acad. Dermatol. Venereol. 2018; 32(9): 1507-14.
  25. Strober B., Gottlieb A.B., Sherif B., Mollon P., Gilloteau I., McLeod L., Fox T., et al. Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept. J. Am. Acad. Dermatol. 2017; 76(4): 655-61.
  26. Ryoo J.Y., Yang H.J., Ji E., Yoo B.K. Meta-analysis of the efficacy and safety of secukinumab for the treatment of plaque psoriasis. Ann. Pharmacother. 2016; 50(5): 341-51.
  27. Ohtsuki M., Morita A., Igarashi A., Imafuku S., Tada Y., Fujita H., et al. Secukinumab improves psoriasis symptoms in patients with inadequate response to cyclosporine A: a prospective study to evaluate direct switch. J. Dermatol. 2017; 44(10): 1105-11.
  28. Reich K., Arenberger P., Mrowietz U., Jazayeri S., Augustin M., Parneix A., et al. Secukinumab shows high and sustained efficacy in nail psoriasis: week 80 results from the TRANSFIGURE study. J. Am. Acad. Dermatol. 2017; 76(6, Suppl. 1): AB232. https://doi.org/10.1016/j.jaad.2017.04.901
  29. Blauvelt A., Prinz J.C., Gottlieb A.B., Kingo K., Sofen H., Ruer-Mulard M., et al.; FEATURE Study Group. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br. J. Dermatol. 2015; 172(2): 484-93.
  30. Langley R.G., Elewski B.E., Lebwohl M., Reich K., Griffiths C.E., Papp K., et al.; ERASURE Study Group; FIXTURE Study Group. Secukinumab in plaque psoriasis - results of two phase 3 trials. N. Engl. J. Med. 2014; 371(4): 326-38.

Copyright (c) 2019 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies